



# Lurex Bio Announces Formation of Scientific Advisory Board

*Board brings together internationally recognized leaders in immunology, oncology, and translational science to guide next-gen immune-engineering platforms.*

FORT LAUDERDALE, FL, UNITED STATES, December 31, 2025 /EINPresswire.com/ -- Lurex Bio Inc., a biotechnology company advancing next-generation immune-engineering platforms, today announced the formation of its Scientific Advisory Board (SAB), composed of internationally recognized leaders in immunology, oncology, translational science, and therapeutic development.

The formation of the [Scientific Advisory Board](#) was spearheaded by Dr. Fred McCall-Perez, Chief Executive Officer of Lurex Bio, who led the identification, vetting, and recruitment of board members to ensure depth across immunology, translational science, and therapeutic development. In his role as CEO, Dr. McCall-Perez will provide strategic oversight and ensure alignment between the company's scientific vision and its execution roadmap.

"Our goal in assembling this board was to bring together scientists who not only understand immune complexity, but who have repeatedly translated that understanding into real therapeutic progress," said Dr. Fred McCall-Perez, CEO of Lurex Bio. "This group provides the depth, rigor, and perspective needed to guide Lurex Bio through its next phase of scientific and translational development."

Lurex Bio's proprietary platforms — including NeoTag™, Atraxis™, Atraxis-X™, and DeltaGate Logic™ — are designed to address immune evasion by enabling precise, non-genetic immune engagement and signal control.

## Scientific Leadership and Advisory Expertise

The Scientific Advisory Board is chaired by Dr. Dusan Kostić, Senior Vice President of Clinical & Medical Affairs at BioXcel Therapeutics.

Additional board members include: • Dr. Vikrant Borse • Dr. Joshua Ghofrani • Dr. Andrej Jedinak • Dr. Maëlig Morvan • Dr. Nicholas M. Valiante • Dr. Abdull J. Massri.

About Lurex Bio Inc. Lurex Bio is a biotechnology innovator focused on re-engineering immune recognition through precision-designed, non-genetic therapeutic platforms.

Contact:

Email: [Press@lurexbio.com](mailto:Press@lurexbio.com)

Tel. 855-LUREXBIO

501 East Las Olas Blvd Ste 300

Fort Lauderdale, Florida 33301

Dr. Fred McCall-Perez

Lurex Bio

+1 855-587-3924

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/879360613>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.